Olmesartan Reduces Inflammatory Biomarkers in Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: Results from the OLIVUS Trial

Overview

Journal Heart Vessels

Specialty Cardiology & Vascular Diseases

Date 2013 Apr 9

PMID 23563752

Citations 3

Authors

Toru Miyoshi

Atsushi Hirohata

Shinichi Usui

Keizo Yamamoto

Takashi Murakami

Issei Komatsubara

Shozo Kusachi

Tohru Ohe

Kazufumi Nakamura

Hiroshi Ito

Affiliations

Soon will be listed here.

Abstract

The OLmesartan on the progression of coronary atherosclerosis: evaluation by IntraVascular UltraSound (OLIVUS) trial demonstrated that an angiotensin II receptor blocker, olmesartan, reduces the rate of coronary atheroma progression as evaluated by intravascular ultrasound in patients with stable angina pectoris undergoing percutaneous coronary intervention. This substudy examined the impact of olmesartan on serum biomarkers and the relationship between biomarker changes and atheroma progression. Patients in the OLIVUS trial (n = 247) were randomly assigned to a control group or the olmesartan group. A subgroup of these patients (n = 135, 55 %) was analyzed at baseline and at 14 months. Patients' characteristics and blood-pressure control were identical between the control group (n = 65) and the olmesartan group (n = 70), and also between the subpopulation and total population. The change in the level of high-sensitivity C-reactive protein (hs-CRP) (mg/l) and adiponectin (μg/ml) was significantly greater in the olmesartan group than in the control group (between-group differences: 0.5 and -0.7; 95 % confidence interval: 0.2-0.8 and -1.3 to -0.1; P = 0.001 and 0.02, respectively). Multiple regression analysis revealed that the nominal changes in total atheroma volume and percent atheroma volume were significantly associated with the nominal change in hs-CRP in the olmesartan group but not in the control group. Olmesartan reduced hs-CRP in patients with stable angina, and this correlated with the change in coronary atheroma.

Citing Articles

Synergistic protective effects of a statin and an angiotensin receptor blocker for initiation and progression of atherosclerosis.

Lee S, Lee S, Thuy N, Kim J, Lee J, Lee O PLoS One. 2019; 14(5):e0215604.

PMID: 31050669 PMC: 6499436. DOI: 10.1371/journal.pone.0215604.

Efficacy study of olmesartan medoxomil on coronary atherosclerosis progression and epicardial adipose tissue volume reduction in patients with coronary atherosclerosis detected by coronary computed tomography angiography: study protocol for a....

Zhou Y, Tian F, Wang J, Yang J, Zhang T, Jing J Trials. 2016; 17:10.

PMID: 26739013 PMC: 4702357. DOI: 10.1186/s13063-015-1097-z.

Impact of tissue characteristics on luminal narrowing of mild angiographic coronary stenosis: assessment of integrated backscatter intravascular ultrasound.

Iwama M, Tanaka S, Noda T, Segawa T, Kawasaki M, Nishigaki K Heart Vessels. 2013; 29(6):750-60.

PMID: 24154856 DOI: 10.1007/s00380-013-0428-9.

References

Naya M, Tsukamoto T, Morita K, Katoh C, Furumoto T, Fujii S . Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients. J Am Coll Cardiol. 2007; 50(12):1144-9. DOI: 10.1016/j.jacc.2007.06.013. View

Kurata A, Nishizawa H, Kihara S, Maeda N, Sonoda M, Okada T . Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int. 2006; 70(10):1717-24. DOI: 10.1038/sj.ki.5001810. View

Tsutamoto T, Nishiyama K, Yamaji M, Kawahara C, Fujii M, Yamamoto T . Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension. Hypertens Res. 2009; 33(2):118-22. DOI: 10.1038/hr.2009.192. View

Miyoshi T, Doi M, Hirohata S, Kamikawa S, Usui S, Ogawa H . Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients. Heart Vessels. 2010; 26(4):408-13. DOI: 10.1007/s00380-010-0060-x. View

Ishiyama Y, Gallagher P, Averill D, Tallant E, Brosnihan K, Ferrario C . Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004; 43(5):970-6. DOI: 10.1161/01.HYP.0000124667.34652.1a. View

Ross R . Atherosclerosis--an inflammatory disease. N Engl J Med. 1999; 340(2):115-26. DOI: 10.1056/NEJM199901143400207. View

Sasaki T, Kuzuya M, Nakamura K, Cheng X, Hayashi T, Song H . AT1 blockade attenuates atherosclerotic plaque destabilization accompanied by the suppression of cathepsin S activity in apoE-deficient mice. Atherosclerosis. 2010; 210(2):430-7. DOI: 10.1016/j.atherosclerosis.2009.12.031. View

Takayama T, Hiro T, Yamagishi M, Daida H, Hirayama A, Saito S . Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J. 2009; 73(11):2110-7. DOI: 10.1253/circj.cj-09-0358. View

Saito M, Ishimitsu T, Minami J, Ono H, Ohrui M, Matsuoka H . Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. Atherosclerosis. 2003; 167(1):73-9. DOI: 10.1016/s0021-9150(02)00380-5. View

10.

Divchev D, Grothusen C, Luchtefeld M, Thoenes M, Onono F, Koch R . Impact of a combined treatment of angiotensin II type 1 receptor blockade and 3-hydroxy-3-methyl-glutaryl-CoA-reductase inhibition on secretory phospholipase A2-type IIA and low density lipoprotein oxidation in patients with coronary artery disease. Eur Heart J. 2008; 29(16):1956-65. DOI: 10.1093/eurheartj/ehn276. View

11.

Nissen S, Tuzcu E, Schoenhagen P, Crowe T, Sasiela W, Tsai J . Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005; 352(1):29-38. DOI: 10.1056/NEJMoa042000. View

12.

Lorenzen J, Neunhoffer H, David S, Kielstein J, Haller H, Fliser D . Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension--results from the EUTOPIA trial. Atherosclerosis. 2009; 209(1):184-8. DOI: 10.1016/j.atherosclerosis.2009.09.009. View

13.

Hirohata A, Yamamoto K, Miyoshi T, Hatanaka K, Hirohata S, Yamawaki H . Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) extension trial. Atherosclerosis. 2011; 220(1):134-8. DOI: 10.1016/j.atherosclerosis.2011.10.013. View

14.

Fliser D, Buchholz K, Haller H . Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation. 2004; 110(9):1103-7. DOI: 10.1161/01.CIR.0000140265.21608.8E. View

15.

Fujiwara W, Izawa H, Ukai G, Yokoi H, Mukaide D, Kinoshita K . Low dose of hydrochlorothiazide, in combination with angiotensin receptor blocker, reduces blood pressure effectively without adverse effect on glucose and lipid profiles. Heart Vessels. 2012; 28(3):316-22. DOI: 10.1007/s00380-012-0246-5. View

16.

Takai S, Jin D, Sakaguchi M, Muramatsu M, Miyazaki M . The regressive effect of an angiotensin II receptor blocker on formed fatty streaks in monkeys fed a high-cholesterol diet. J Hypertens. 2005; 23(10):1879-86. DOI: 10.1097/01.hjh.0000182527.52063.32. View

17.

Mervaala E, Muller D, Park J, Schmidt F, Lohn M, Breu V . Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension. 1999; 33(1 Pt 2):389-95. DOI: 10.1161/01.hyp.33.1.389. View

18.

Ridker P . Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003; 107(3):363-9. DOI: 10.1161/01.cir.0000053730.47739.3c. View

19.

Nakamura M, Yock P, Bonneau H, Kitamura K, Aizawa T, Tamai H . Impact of peri-stent remodeling on restenosis: a volumetric intravascular ultrasound study. Circulation. 2001; 103(17):2130-2. DOI: 10.1161/01.cir.103.17.2130. View

20.

Nissen S, Nicholls S, Sipahi I, Libby P, Raichlen J, Ballantyne C . Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006; 295(13):1556-65. DOI: 10.1001/jama.295.13.jpc60002. View